Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone Combined With JAK Inhibitors in TEN
NCT06119490Phase 1Recruiting
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in toxic epidermal necrolysis (TEN) comparing Abrocitinib Arm with Tofacitinib Arm (2 arms). Primary endpoint: Time to Reepithelization at 8 weeks. Started Jul 2023; status: recruiting.
02
Drugs
abrocitinibtofacitinib
03
Conditions
toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on NCT06119490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06119490.